Peter Francis

Company: Ray Therapeutics

Job title: Chief Scientific Officer, Chief Medical Officer

Seminars:

Exploring Disease Indication & Endpoint Selection for Ophthalmic Gene Therapy Trials to Unlock Optimal Results 11:30 am

Showcasing how to replicate LUXTERNA results in subsequent RPE65 gene therapies Identifying the ideal volume and best vehicle Evaluating promotor usage, injection point and AAV virus formulationRead more

day: Conference Day Two